Skip to main content
Signal8

InMed Pharmaceuticals Inc. Form SCHEDULE 13D — Nov 12, 2026

Form SCHEDULE 13DFiled Nov 12, 2026, 5:00 PM ET0001193125-26-458677Original filing

Fairmount Funds Management, Fairmount Healthcare Fund II L.P., Peter Harwin and Tomas Kiselak filed a Schedule 13D disclosing beneficial ownership of 10,555,507 shares, or 19.99%, of Mentari Therapeutics' common stock as of November 6, 2026. The stake stems from Fairmount's multi-stage backing of Mentari, including $50.0 million of 12% convertible notes and participation in an approximately $490.0 million pre-closing financing, culminating in the November 6, 2026 reverse merger in which InMed Pharmaceuticals became Mentari Therapeutics via a 1-for-10 consolidation and Nevada redomestication.

Key figures

Shares Owned
10555507
Percent Owned
19.99%
Shares Outstanding
52813914
Lockup period
180 days after First Effective Time
Common stock purchase price
$119,999,263 (including Convertible Notes principal and accrued interest contributed in the Mentari Pre-Closing Financing)
Convertible notes principal
$50.0 million at 12% interest
Reverse consolidation ratio
1-for-10
Preclosing financing commitment
~$490.0 million (including $52.7 million of Convertible Notes principal and accrued interest)
Series a preferred purchase price
$200,000
Shares issuable on series a conversion
4013000
Shares issuable on prefunded warrant exercise
1468222

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.